{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:32:14Z","timestamp":1793194334385,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pediatr-neonatol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pediatrics &amp; Neonatology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.pedneo.2025.11.013","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T16:19:28Z","timestamp":1772900368000},"page":"596-602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Drug-associated torsades de pointes and QT prolongation in infants: A focused real-world disproportionality analysis pharmacovigilance study"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3811-6503","authenticated-orcid":false,"given":"Kannan","family":"Sridharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gowri","family":"Sivaramakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pedneo.2025.11.013_bib1","series-title":"StatPearls [Internet]","article-title":"Torsade de Pointes","author":"Cohagan","year":"2024"},{"key":"10.1016\/j.pedneo.2025.11.013_bib2","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00228-018-2537-y","article-title":"Acquired drug-induced long QTc: new insights coming from a retrospective study","volume":"74","author":"De Vecchis","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pedneo.2025.11.013_bib3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jfma.2018.01.016","article-title":"Prevalence of the risk factors for QT prolongation and associated drug-drug interactions in a cohort of medical inpatients","volume":"118","author":"Khan","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.pedneo.2025.11.013_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1259611","article-title":"Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.pedneo.2025.11.013_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.966331","article-title":"Drug-induced torsades de pointes: disproportionality analysis of the United States Food and Drug Administration adverse event reporting system","volume":"9","author":"Wu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.pedneo.2025.11.013_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5114\/ait.2021.103628","article-title":"Drug utilisation in adult, paediatric and neonatal intensive care units, with an emphasis on systemic antimicrobials","volume":"53","author":"Sridharan","year":"2021","journal-title":"Anaesthesiol Intensive Ther"},{"key":"10.1016\/j.pedneo.2025.11.013_bib9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.yjmcc.2013.09.001","article-title":"Developmental changes in expression and biophysics of ion channels in the canine ventricle","volume":"64","author":"Cordeiro","year":"2013","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pedneo.2025.11.013_bib10","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212608","article-title":"Neonatal pharmacology and clinical implications","volume":"8","author":"Ruggiero","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.pedneo.2025.11.013_bib11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/jcdd9060184","article-title":"Resuscitated Sudden Cardiac Arrest of a Neonate with Congenital LQT Syndrome-Associated Torsades de Pointes: a Case Report and Literature Review","volume":"9","author":"Hsu","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.pedneo.2025.11.013_bib12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4212\/cjhp.v69i3.1552","article-title":"Drug-Induced QT interval prolongation in children: are the kids alright?","volume":"69","author":"Tisdale","year":"2016","journal-title":"Can J Hosp Pharm"},{"key":"10.1016\/j.pedneo.2025.11.013_bib13","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.yjmcc.2007.11.015","article-title":"Cardiac potassium channel dysfunction in sudden infant death syndrome","volume":"44","author":"Rhodes","year":"2008","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pedneo.2025.11.013_bib14","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40272-024-00657-3","article-title":"Adverse event profile of first-line drugs for treating patent ductus Arteriosus in neonates: a disproportionality analysis Study of USFDA adverse event reporting System","volume":"26","author":"Sridharan","year":"2024","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.pedneo.2025.11.013_bib15","series-title":"Advanced concepts in arrhythmias","first-page":"293","article-title":"Polymorphic ventricular tachycardia","author":"Marriott","year":"1998"},{"key":"10.1016\/j.pedneo.2025.11.013_bib16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/(SICI)1099-1557(199809\/10)7:5<351::AID-PDS368>3.0.CO;2-0","article-title":"Definitions and basic requirements for the use of terms for reporting adverse drug reactions (XI): cardiovascular system disorders","volume":"7","author":"Bankowski","year":"1998","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.pedneo.2025.11.013_bib18","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case-non-case studies: principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.pedneo.2025.11.013_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/20420986221125006","article-title":"Pharmacovigilance: reporting requirements throughout a product's lifecycle","volume":"13","author":"Lucas","year":"2022","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.pedneo.2025.11.013_bib21","series-title":"Practical aspects of signal detection in pharmacovigilance. Report of CIOMS working group VIII","author":"World Health","year":"2010"},{"key":"10.1016\/j.pedneo.2025.11.013_bib22","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"10.1016\/j.pedneo.2025.11.013_bib23","unstructured":"Hospira, Inc. Atracurium label. USA: Hospira, Inc. Available at https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=4665 Accessed October 25, 2024."},{"key":"10.1016\/j.pedneo.2025.11.013_bib24","unstructured":"Ben Venue Laboratories, Inc. Vecuronium label. Ben Venue Laboratories, Inc: USA. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/075549s013lbl.pdf Accessed October 23, 2024."},{"key":"10.1016\/j.pedneo.2025.11.013_bib25","first-page":"577","article-title":"The effects of midazolam followed by administration of either vecuronium or atracurium on the QT interval in humans","volume":"12","author":"Michaloudis","year":"1995","journal-title":"Eur J Anaesthesiol"},{"key":"10.1016\/j.pedneo.2025.11.013_bib26","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1177\/0300060518764185","article-title":"Corrected QT interval prolongation during anesthetic induction for laryngeal mask airway insertion with or without cisatracurium","volume":"46","author":"Xuan","year":"2018","journal-title":"J Int Med Res"},{"key":"10.1016\/j.pedneo.2025.11.013_bib27","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/1053-0770(92)90145-W","article-title":"Electrophysiological effects of atracurium and vecuronium on normal and denervated hearts","volume":"6","author":"Alvarez","year":"1992","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.pedneo.2025.11.013_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1156658","article-title":"Case report: torsade de pointes induced by the bigeminy result from retrograde ventriculoatrial activation in VVI pacing and resolved by intentional atrial pacing","volume":"10","author":"Chu","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.pedneo.2025.11.013_bib29","unstructured":"Rafa Laboratories, Ltd. Midazolam label. Rafa Laboratories, Ltd.: Israel. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/216359s000lbl.pdf Access October 22, 2024."},{"key":"10.1016\/j.pedneo.2025.11.013_bib30","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/00003246-200205000-00008","article-title":"Short-term effects of intravenous benzodiazepines on autonomic neurocardiac regulation in humans: a comparison between midazolam, diazepam, and lorazepam","volume":"30","author":"Agelink","year":"2002","journal-title":"Crit Care Med"},{"key":"10.1016\/j.pedneo.2025.11.013_bib31","unstructured":"Par Pharmaceutical Companies, Inc. Captopril label. Par Pharmaceutical Companies, Inc.:NY. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/018343s084lbl.pdf Accessed October 22, 2024."},{"key":"10.1016\/j.pedneo.2025.11.013_bib32","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/hrt.67.5.355","article-title":"Comparative electrophysiological effects of captopril or hydralazine combined with nitrate in patients with left ventricular dysfunction and inducible ventricular tachycardia","volume":"67","author":"Bashir","year":"1992","journal-title":"Br Heart J"},{"key":"10.1016\/j.pedneo.2025.11.013_bib33","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1097\/00000542-200011000-00036","article-title":"Ventricular tachycardia caused by hyperkalemia after administration of hypertonic mannitol","volume":"93","author":"Seto","year":"2000","journal-title":"Anesthesiology"}],"container-title":["Pediatrics &amp; Neonatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875957226000367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875957226000367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:35:11Z","timestamp":1793190911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875957226000367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1875957226000367"],"URL":"https:\/\/doi.org\/10.1016\/j.pedneo.2025.11.013","relation":{},"ISSN":["1875-9572"],"issn-type":[{"value":"1875-9572","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-associated torsades de pointes and QT prolongation in infants: A focused real-world disproportionality analysis pharmacovigilance study","name":"articletitle","label":"Article Title"},{"value":"Pediatrics & Neonatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pedneo.2025.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Taiwan Pediatric Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}